| Alzheimer Disease |
1 |
1 |
| Mild Cognitive Impairment |
0 |
0.81 |
| Brain |
0 |
0.51 |
| Cognitive Impairment |
0 |
0.43 |
| Biomarker |
0 |
0.4 |
| Impairment |
0 |
0.3 |
| Medicare |
0 |
0.3 |
| Amyloid-Beta |
0 |
0.2 |
| Cerebrospinal Fluid |
0 |
0.2 |
| Medicaid |
0 |
0.2 |
| Patient Safety |
0 |
0.18 |
| Revenue and Practice Management |
0 |
0.18 |
| Thromboembolism |
0 |
0.18 |
| Geriatrics |
0 |
0.17 |
| Adverse Effects |
0 |
0.1 |
| Anticoagulation Therapy |
0 |
0.1 |
| Antiplatelet Agent |
0 |
0.1 |
| Aspirin |
0 |
0.1 |
| Blood |
0 |
0.1 |
| Dementia |
0 |
0.1 |
| Edema |
0 |
0.1 |
| Hemorrhage |
0 |
0.1 |
| Insurance |
0 |
0.1 |
| Intravenous |
0 |
0.1 |
| Magnetic Resonance Imaging |
0 |
0.1 |
| Maryland |
0 |
0.1 |
| Memory |
0 |
0.1 |
| Tau Protein |
0 |
0.1 |
| Thrombolytic Therapy |
0 |
0.1 |
| Vitamin |
0 |
0.1 |